Even the flower plague is on fire again! In the first quarter, more than 1.5 billion sales were available in more than 10 countries and regions.

On August 11, Ealing Pharmaceuticals announced that it had received a drug registration certificate approved by the Philippine Food and Drug Administration to approve the registration of the company's drug Lianhua Qing plague capsules in accordance with traditional Plant Medicine standards in the Philippines.
the first quarter of 2020, Lianhua Qing plague products revenue of 1.542 billion yuan, accounting for 66.07 percent of the company's total revenue.
to date, Lianhua Qing Plague Capsules has been licensed for listing in more than 10 countries and regions, including Hong Kong, Macau and Brazil, Indonesia, Canada, Mozambique, Romania and Thailand.
the basic situation registered in the Philippines, Lianhua Qing plague products are the leading products of Eling Pharmaceuticals, the national basic drug catalogue and the national health insurance catalogue (Class A) varieties, mainly used for the treatment of cold, influenza-related diseases.
Lianhua Qing plague products have been repeatedly included in the National Health and Health Commission, the State Administration of Traditional Chinese Medicine cold, influenza-related disease diagnosis and treatment program.
2020 Lianhua Qing plague capsules/particles are listed as the National Health And Health Commission and the State Administration of Traditional Chinese Medicine jointly issued the "new coronavirus infection of pneumonia diagnosis and treatment program" (trial 4/5/6/7 version) recommended medication.
April 12, 2020, the State Drug Administration approved Lianhua Qing plague capsules/particles to add a new adaptation of "new coronavirus pneumonia light, common type" on the basis of the original approved adaptation.
2019 to Ling Pharmaceuticals' Lianhua Qing plague products to achieve operating income of 1.703 billion yuan, accounting for 29.24% of the company's total operating income.
the first quarter of 2020, Lianhua Qing plague products achieved operating income of 1.542 billion yuan, accounting for 66.07 percent of the company's total operating income. according to
meters of intranet data, in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal sales of more than 1 billion yuan.
Ering Pharmaceuticals said that the Lianhua Qing plague capsule was approved by the Philippine Food and Drug Administration for drug registration, marking the company's eligibility to sell the product as a drug in the Philippine market, the company to expand overseas markets have a positive impact.
To date, Lianhua Qing plague capsules have been registered as "traditional Chinese medicine", "drug", "plant medicine", "natural health products", "food supplements", "modern plant medicine" and "natural medicine" respectively in Hong Kong, Macao and Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore and Laos.
currently accounts for a low proportion of the company's total operating income, which does not have a significant impact on the company's operating performance.
.